Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23349325 | 0.71 | — | — | |
| SCHEMBL23065253 | 0.71 | ADRA1D (0.31) | ADRA1AADRA1D | |
| SCHEMBL5024271 | 0.69 | — | — | |
| SCHEMBL5738285 | 0.69 | ALOX15 (0.42) | ADRA1AADRA1D | |
| SCHEMBL3226591 | 0.67 | ADRA1A (0.31) | ADRA1AADRA1D | |
| SCHEMBL29348293 | 0.67 | ADRA1D (0.31) | ADRA1AADRA1D | |
| SCHEMBL23958132 | 0.65 | ADRA1D (0.30) | ADRA1AADRA1D | |
| SCHEMBL4071580 | 0.65 | ADRA1A (0.33) | ADRA1AADRA1D | |
| SCHEMBL7342787 | 0.65 | ADRA1A (0.38) | ADRA1AADRA1D | |
| SCHEMBL13424007 | 0.65 | P2RX7 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | claimed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | claimed |
| EP-2451814-A2 | FUSED IMIDAZOLES AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS E.G. MALARIA | IRM LLC (BM) | 2012-05-16 | — | — | EP | claimed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | claimed |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4206184-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-05 | — | — | EP | disclosed |
| EP-3746432-B1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | disclosed |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006130588-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D BETA-LACTAMASES INHIBITORS | WYETH (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7112582-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1499621-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASES INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214812-A1 | 4-Substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2004-10-28 | — | — | US | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
| WO-2003093279-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214812-A1 | 4-Substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | DDC, AADAC, ALDH7A1 | ADRA1A 2364/4885ADRA1D 1811/4885 |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, MGAM, PGLS | ADRA1A 2939/4885ADRA1D 2123/4885 |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | ADRA1A 3337/4885ADRA1D 3941/4885 |
| US-20230312474-A1 | PHENOL DERIVATIVE | TYR, NCOR1, BET1 | ADRA1A 545/4885ADRA1D 483/4885 |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, BPGM, B2M | ADRA1A 1911/4885ADRA1D 2078/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | ADRA1A 1585/4885ADRA1D 1634/4885 |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | ADRA1A 2324/4885ADRA1D 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.